MARKET

MYOV

MYOV

MYOVANT SCIENCES
NYSE

Real-time Quotes | Nasdaq Last Sale

19.98
+0.88
+4.61%
Closed 17:50 07/29 EDT
OPEN
19.40
PREV CLOSE
19.10
HIGH
20.10
LOW
18.66
VOLUME
1.15M
TURNOVER
--
52 WEEK HIGH
30.90
52 WEEK LOW
13.42
MARKET CAP
1.83B
P/E (TTM)
-7.0626
1D
5D
1M
3M
1Y
5Y
CAN, DAO, NEGG among mid-day movers
Gainers: Bit Digital (BTBT) +51%.Infinity Pharmaceuticals (INFI) +46%.NanoVibronix (NAOV) +40%.Tilray (TLRY) +26%.Flora Growth Corp. (FLGC) +25%.Youdao (DAO) +24%.Grove (GRVI) +22%.Zhangmen Education (ZME) +23%.First High-School Education (FHS) +22%.Canaan...
Seekingalpha · 1d ago
Myovant Sciences shares fall after Q1 earnings miss
Myovant Sciences shares slide ([[MYOV]] -10.8%) after the company reported first-quarter results that missed Wall Street estimates.Quarterly revenue rose 23% to $41.06M, but missed analysts' average estimate by $20.76M.The company's
Seekingalpha · 1d ago
Infinity Pharmaceuticals, Grove leads healthcare gainers; Dyadic, EyeGate Pharmaceuticals among major losers
Gainers: Infinity Pharmaceuticals (INFI) +62%, Grove (GRVI) +26%, Shineco (TYHT) +24%, Tilray (TLRY) +22%, NeuroMetrix (NURO) +19%.Losers: Dyadic (DYAI) -14%, EyeGate Pharmaceuticals (EYEG) -13%, NanoViricides (NNVC) -13%, Myovant Sciences (MYOV) -9%, Vivo...
Seekingalpha · 1d ago
Myovant Sciences (MYOV) Reports Q1 Loss, Misses Revenue Estimates
Zacks.com · 1d ago
Recap: Myovant Sciences Q1 Earnings
  Shares of Myovant Sciences (NYSE:MYOV) rose 1.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 81.08% year over year to ($0.67), which missed the estimate of ($0.33).
Benzinga · 1d ago
Myovant Sciences Fiscal Q1 Loss Expands; Revenue Increases
MT Newswires · 2d ago
BRIEF-Myovant Sciences Posts Quarterly Loss Per Share $0.67
reuters.com · 2d ago
Myovant Sciences EPS misses by $0.36, misses on revenue
Myovant Sciences (MYOV): Q1 GAAP EPS of -$0.67 misses by $0.36.Revenue of $41.06M (+23.2% Y/Y) misses by $20.76M.Myovant remains well-capitalized with cash, cash equivalents, marketable securities, and committed funding of
Seekingalpha · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MYOV. Analyze the recent business situations of MYOVANT SCIENCES through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MYOV stock price target is 35.17 with a high estimate of 55.00 and a low estimate of 24.00.
EPS
Institutional Holdings
Institutions: 137
Institutional Holdings: 47.19M
% Owned: 51.58%
Shares Outstanding: 91.48M
TypeInstitutionsShares
Increased
39
6.08M
New
26
1.40M
Decreased
19
1.84M
Sold Out
29
3.08M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Chairman/Director
Myrtle Potter
Chief Executive Officer/Director
David Marek
Chief Financial Officer/Chief Accounting Officer
Frank Karbe
General Counsel/Secretary
Matthew Lang
Other/Director
Adele Gulfo
Other
Juan Camilo Arjona Ferreira
Lead Director/Independent Director
Kathleen Sebelius
Director
Hiroshi Nomura
Independent Director
Terrie Curran
Independent Director
Mark Guinan
No Data
  • All
  • Financials
  • Insiders
More
About MYOV
Myovant Sciences Ltd, is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment women’s health and endocrine diseases. Its lead product candidate is Relugolix, which is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is also advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. The Company is developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility.

Webull offers kinds of Myovant Sciences Ltd stock information, including NYSE:MYOV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYOV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYOV stock methods without spending real money on the virtual paper trading platform.